CSPC Pharmaceutical Group Limited

SEHK:1093 Rapport sur les actions

Capitalisation boursière : HK$65.9b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

CSPC Pharmaceutical Group Gestion

Gestion contrôle des critères 2/4

Le PDG CSPC Pharmaceutical Group's est Cuilong Zhang, nommé en May2022, a un mandat de 2.25 ans. La rémunération annuelle totale est CN¥ 13.47M, composée du salaire de 5.1% et des bonus 94.9%, y compris les actions et options de la société. détient directement 0.034% des actions de la société, d'une valeur de HK$ 24.36M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2.9 ans et 7.4 ans.

Informations clés

Cuilong Zhang

Directeur général

CN¥13.5m

Rémunération totale

Pourcentage du salaire du PDG5.1%
Durée du mandat du directeur général2.3yrs
Propriété du PDG0.04%
Durée moyenne d'occupation des postes de direction2.3yrs
Durée moyenne du mandat des membres du conseil d'administration7.5yrs

Mises à jour récentes de la gestion

Recent updates

CSPC Pharmaceutical Group Limited (HKG:1093) Investors Are Less Pessimistic Than Expected

Aug 08
CSPC Pharmaceutical Group Limited (HKG:1093) Investors Are Less Pessimistic Than Expected

Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly

Jun 17
Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly

CSPC Pharmaceutical Group Limited Just Recorded A 20% Revenue Beat: Here's What Analysts Think

May 29
CSPC Pharmaceutical Group Limited Just Recorded A 20% Revenue Beat: Here's What Analysts Think

CSPC Pharmaceutical Group (HKG:1093) Has Announced A Dividend Of CN¥0.14

May 21
CSPC Pharmaceutical Group (HKG:1093) Has Announced A Dividend Of CN¥0.14

CSPC Pharmaceutical Group (HKG:1093) Will Pay A Dividend Of CN¥0.14

Apr 29
CSPC Pharmaceutical Group (HKG:1093) Will Pay A Dividend Of CN¥0.14

There's Reason For Concern Over CSPC Pharmaceutical Group Limited's (HKG:1093) Price

Apr 22
There's Reason For Concern Over CSPC Pharmaceutical Group Limited's (HKG:1093) Price

CSPC Pharmaceutical Group's (HKG:1093) Dividend Will Be CN¥0.14

Apr 01
CSPC Pharmaceutical Group's (HKG:1093) Dividend Will Be CN¥0.14

CSPC Pharmaceutical Group Limited (HKG:1093) Shares Could Be 49% Below Their Intrinsic Value Estimate

Jan 22
CSPC Pharmaceutical Group Limited (HKG:1093) Shares Could Be 49% Below Their Intrinsic Value Estimate

Some Confidence Is Lacking In CSPC Pharmaceutical Group Limited's (HKG:1093) P/E

Jan 04
Some Confidence Is Lacking In CSPC Pharmaceutical Group Limited's (HKG:1093) P/E

Are Investors Undervaluing CSPC Pharmaceutical Group Limited (HKG:1093) By 36%?

Oct 22
Are Investors Undervaluing CSPC Pharmaceutical Group Limited (HKG:1093) By 36%?

Is CSPC Pharmaceutical Group (HKG:1093) A Risky Investment?

Sep 21
Is CSPC Pharmaceutical Group (HKG:1093) A Risky Investment?

CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 62% Above Its Share Price

Jul 09
CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 62% Above Its Share Price

Does CSPC Pharmaceutical Group (HKG:1093) Have A Healthy Balance Sheet?

Jun 20
Does CSPC Pharmaceutical Group (HKG:1093) Have A Healthy Balance Sheet?

CSPC Pharmaceutical Group's (HKG:1093) Shareholders Will Receive A Bigger Dividend Than Last Year

Jun 01
CSPC Pharmaceutical Group's (HKG:1093) Shareholders Will Receive A Bigger Dividend Than Last Year

CSPC Pharmaceutical Group (HKG:1093) Is Increasing Its Dividend To CN¥0.11

Apr 04
CSPC Pharmaceutical Group (HKG:1093) Is Increasing Its Dividend To CN¥0.11

CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 92% Above Its Share Price

Mar 12
CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 92% Above Its Share Price

We Think CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt With Ease

Dec 26
We Think CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt With Ease

Analyse de la rémunération des PDG

Comment la rémunération de Cuilong Zhang a-t-elle évolué par rapport aux bénéfices de CSPC Pharmaceutical Group?
DateRémunération totaleSalaireBénéfices de l'entreprise
Jun 30 2024n/an/a

CN¥6b

Mar 31 2024n/an/a

CN¥6b

Dec 31 2023CN¥13mCN¥693k

CN¥6b

Sep 30 2023n/an/a

CN¥6b

Jun 30 2023n/an/a

CN¥6b

Mar 31 2023n/an/a

CN¥6b

Dec 31 2022CN¥11mCN¥693k

CN¥6b

Sep 30 2022n/an/a

CN¥6b

Jun 30 2022n/an/a

CN¥6b

Mar 31 2022n/an/a

CN¥6b

Dec 31 2021CN¥9mCN¥693k

CN¥6b

Sep 30 2021n/an/a

CN¥6b

Jun 30 2021n/an/a

CN¥6b

Mar 31 2021n/an/a

CN¥5b

Dec 31 2020CN¥9mCN¥693k

CN¥5b

Sep 30 2020n/an/a

CN¥4b

Jun 30 2020n/an/a

CN¥4b

Mar 31 2020n/an/a

CN¥4b

Dec 31 2019CN¥7mCN¥693k

CN¥4b

Sep 30 2019n/an/a

CN¥4b

Jun 30 2019n/an/a

CN¥3b

Mar 31 2019n/an/a

CN¥3b

Dec 31 2018CN¥4mCN¥298k

CN¥3b

Rémunération vs marché: La rémunération totale de Cuilong ($USD 1.89M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché Hong Kong ($USD 913.61K ).

Rémunération et revenus: La rémunération de Cuilong a augmenté de plus de 20 % tandis que les bénéfices de l'entreprise ont chuté de plus de 20 % au cours de l'année écoulée.


PDG

Cuilong Zhang (55 yo)

2.3yrs

Titularisation

CN¥13,472,000

Compensation

Mr. Cuilong Zhang has been the Vice Chairman of CSPC Pharmaceutical Group Ltd since May 21, 2019 and serves as its Chief Executive Officer since May 27, 2022. He was Rotating Chief Executive Officer of CSP...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Dongchen Cai
Executive Chairman27.4yrsCN¥26.68m24.16%
CN¥ 15.9b
Cuilong Zhang
Vice-Chairman & CEO2.3yrsCN¥13.47m0.043%
CN¥ 28.2m
Chunlei Li
Executive Director & Chief Scientist6.8yrsCN¥9.42m0.039%
CN¥ 25.4m
Weidong Pan
Executive Directorno dataCN¥4.92m0.013%
CN¥ 8.5m
Huaiyu Wang
Executive Directorno dataCN¥5.74m0.013%
CN¥ 8.5m
Zhenguo Wang
Executive Directorno dataCN¥4.90m0.013%
CN¥ 8.5m
Hao Jiang
Executive Directorno dataCN¥4.02m0.026%
CN¥ 16.9m
Xin Cai
Group Executive Presidentno datapas de donnéespas de données
Bing Yao
Executive Directorless than a yearpas de donnéespas de données
Yongjun Liu
Executive president & President of Global Research and Developmentno datapas de donnéespas de données
Tai On Lo
Company Secretary3.7yrspas de donnéespas de données

2.3yrs

Durée moyenne de l'emploi

54.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de 1093 est considérée comme expérimentée (ancienneté moyenne 2.9 ans).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Dongchen Cai
Executive Chairman27.4yrsCN¥26.68m24.16%
CN¥ 15.9b
Cuilong Zhang
Vice-Chairman & CEO6.2yrsCN¥13.47m0.043%
CN¥ 28.2m
Chunlei Li
Executive Director & Chief Scientist6.8yrsCN¥9.42m0.039%
CN¥ 25.4m
Weidong Pan
Executive Director17.9yrsCN¥4.92m0.013%
CN¥ 8.5m
Huaiyu Wang
Executive Director13.9yrsCN¥5.74m0.013%
CN¥ 8.5m
Zhenguo Wang
Executive Director12.7yrsCN¥4.90m0.013%
CN¥ 8.5m
Hao Jiang
Executive Director3.8yrsCN¥4.02m0.026%
CN¥ 16.9m
Xin Cai
Group Executive Presidentless than a yearpas de donnéespas de données
Bing Yao
Executive Directorless than a yearpas de donnéespas de données
Chun Kwok Au
Independent Non-Executive Director3.7yrsCN¥340.00kpas de données
Bo Wang
Independent Non-Executive Director11.8yrsCN¥142.00kpas de données
Chuan Chen
Independent Non-Executive Director8.3yrsCN¥142.00kpas de données

7.5yrs

Durée moyenne de l'emploi

54.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 1093 sont considérés comme expérimentés (ancienneté moyenne 7.4 ans).